Sara Markey
Psychiatry · Denver, CONPI 1477630473
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,731 of the $5,490 with a category attached, or 86.2%. 17 manufacturers reported payments, led by Neuronetics, Inc. at 24.5% of the total. Reporting peaked in 2022 at $2,957 and has fallen 81.4% since, to $549 in 2025. Among psychiatry clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $47.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$1K
- Brainsway USA Inc$1K
- AbbVie$664
- Otsuka America Pharmaceutical, Inc.$511
- Alkermes, Inc.$422
- Neurocrine Biosciences, Inc.$301
- plus $1K from 11 others
Across 30 payments — averaging $6792.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$74K
- Bioxcel Therapeutics, Inc.$54K
- Janssen Research & Development, LLC$32K
- Avanir Pharmaceuticals, Inc.$31K
- Biogen$13K
What the payments were for
- Travel & lodging$75914%
- Food & beverage$4,73186%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 3 | $1,344 |
| Brainsway USA Inc | 1 | $1,234 |
| AbbVie(2 entities) | 26 | $664 |
| Otsuka America Pharmaceutical, Inc. | 19 | $511 |
| Alkermes, Inc. | 21 | $422 |
| Neurocrine Biosciences, Inc. | 9 | $301 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $295 |
| Axsome Therapeutics, Inc. | 5 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $146 |
| Johnson & Johnson | 1 | $121 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,344
- Brainsway Deep TMS$1,234
- VRAYLAR$250
- Auvelity$229
- INGREZZA$121
- SPRAVATO$121
- NUEDEXTA$121
How this compares
$5,490 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,398 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $713 |
| Lorazepam | 13 | $262 |
| Diazepam | 16 | $112 |
| Bupropion XlBupropion Hcl | 12 | $81 |
| Alprazolam | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $37 | $16,39811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.
Other psychiatry in Denver
- Jeffrey RichmondDenver$424K
- Brenda CzabanDenver$25K
- Robert ClarkDenver$14K
- Katy McLaughlinDenver$7K
- Stephen PopkinDenver$6K
- Joseph MendozzaDenver$3K
- John HardyPueblo$828K
- Larry SandersLittleton$760K
- Jennifer FrenchGlendale$115K
- Charles ParkLone Tree$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.